Paracetamol maker Granules India posts 23 per cent rise in Q3 profit, Health News, ET HealthWorld

Bengaluru: Pharmaceutical company Granules India Ltd, reported a 23 per cent rise in third-quarter profit on Tuesday, propelled by strong demand for the painkiller drug Paracetamol. Consolidated profit rose to 1.24 billion rupees ($15.22 million) for the three months ended Dec. 31, from 1.01 billion rupees a year earlier. Consolidated revenue for the company rose nearly 15 per cent to 11.46 billion rupees, “primarily driven by higher Paracetamol API sales in the US,” the company said in an exchange filing. “Opportunities in Paracetamol are likely to continue and our geography…

Read More

Strides gets USFDA nod for generic drug with 180-day exclusivity – ET HealthWorld

US Food and Drug Administration (USFDA) New Delhi: Drug firm Strides Pharma Science on Saturday said its subsidiary has received approval from the US health regulator to market Ibuprofen Oral Suspension, used for the treatment of pain and fever, in the American market. Singapore-based Strides Pharma Global Pte, a step-down wholly-owned subsidiary of the company, has received approval for its product from the US Food and Drug Administration (USFDA). The company’s product is therapeutically equivalent to GlaxoSmithKline Consumer Healthcare Holdings’ Advil Concentrated Drops, Strides Pharma Science said in a statement.…

Read More

NPPA approves price rise of 50 per cent for carbamazepine, ranitidine, ibuprofen – ET HealthWorld

The national drug pricing regulator NPPA on Friday said it has allowed a one-time increase of 50 per cent in the ceiling prices of nine scheduled formulations of three drugs – carbamazepine, ranitidine and ibuprofen – to ensure their availability. These drugs are used as the first line of treatment and are important to the public health programme of the country, the National Pharmaceutical Pricing Authority (NPPA) said in its order. NPPA, in its meeting on June 28, deliberated upon the case of upward price revision of the formulations of…

Read More

Ibuprofen safe, doesn’t raise Covid death risk: Study – ET HealthWorld

London: Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, is safe and does not lead to higher rates of death or severe disease in patients hospitalised with Covid-19, according to a new observational study of more than 72,000 people in the UK. NSAIDs are common treatments for acute pain and rheumatological diseases such as rheumatoid arthritis and osteoarthrosis. Early in the pandemic, there was debate on whether the use of such drugs increased the severity of Covid-19, which led to urgent calls for investigations between NSAIDs and Covid-19. But, the study,…

Read More

ICMR advises against NSAIDs, says some painkillers found to worsen Covid-19 – ET HealthWorld

Some painkillers like Ibuprofen are found to worsen Covid-19, known to be harmful to heart failure patients and may increase risk of kidney damage, the ICMR said as it advised against taking non-steroidal anti-inflammatory drugs (NSAIDs) and recommended taking paracetamol, if needed, during the disease. Listing a series of frequently asked questions (FAQs) for patients with hypertension, diabetes and heart diseases, the ICMR said currently there is no evidence that BP medications — two group of drugs ACE inhibitors and angiotensin receptor blockers (ARBs) — increase the susceptibility or severity…

Read More